anti-HLA humanized mAbs (Wakunaga Pharmaceutical/Kyoto Prefectural Univ/Kanazawa Univ)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Nameanti-HLA humanized mAbs (Wakunaga Pharmaceutical/Kyoto Prefectural Univ/Kanazawa Univ)
Drug Alias Nameanti-HLA-B61 humanized mAb (Wakunaga Pharmaceutical/Kyoto Prefectural Univ/Kanazawa Univ)anti-HLA-Bw4 humanized mAb (Wakunaga Pharmaceutical/Kyoto Prefectural Univ/Kanazawa Univ)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionHuman leukocyte antigen inhibitors
TargetsHuman leukocyte antigen
Therapy Area/IndicationsMultiple MyelomaLymphoma, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJapan
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesWakunaga Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesKyoto Prefectural UniversityKanazawa UniversityWakunaga Pharmaceutical Co Ltd
Active IndicationsN/A
Inactive IndicationsMultiple MyelomaLymphoma, B-Cell

Other Information

ATC CodeN/A
Related LinksN/A